Used in the treatment of cancers driven by NTRK gene fusions, particularly in patients who have developed resistance to prior TRK inhibitors. It functions as a next-generation TRK inhibitor with activity against a broad range of TRK fusion proteins, including those with solvent front, gatekeeper, and xDFG mutations. Shows promise in pediatric and adult tumors such as certain sarcomas, gliomas, and other solid tumors where NTRK fusions are present. Designed to cross the blood-brain barrier, making it effective in treating central nervous system tumors and brain metastases. Currently under clinical investigation in trials involving patients with advanced or refractory cancers.